BioNTech präsentiert auf der ASCO-Jahrestagung 2024 klinische Daten-Updates zu innovativen Immuntherapie-Kandidaten
May 21, 2024 06:45 ET
|
BioNTech SE
MAINZ, Deutschland, 21. Mai 2024 – BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird auf der diesjährigen Jahrestagung der American Society of Clinical Oncology („ASCO“), die vom 31....
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
May 21, 2024 06:45 ET
|
BioNTech SE
MAINZ, Germany, May 21, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected programs from the Company’s diversified immuno-oncology pipeline at...
BioNTech und Autolus schließen strategische Kollaboration zur Weiterentwicklung der Pipeline und Ausbau fortgeschrittener CAR-T-Zelltherapie-Programme
February 08, 2024 05:45 ET
|
BioNTech SE
Die Unternehmen nutzen in der strategischen Zusammenarbeit Produktionskapazitäten, kommerzielle Infrastruktur sowie Technologien mit dem Ziel, die autologen CAR-T-Programme beider Unternehmen...
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
February 08, 2024 05:45 ET
|
BioNTech SE
Strategic alliance leverages manufacturing and commercial infrastructure as well as technology with the aim to advance both companies’ autologous CAR-T programs towards market, pending market...
Advanced Therapy Medicinal Products Market to Accumulate a Valuation of USD 61.5 Billion by 2030, Advancing at a 13.4% CAGR | MarketDigits
February 06, 2024 07:15 ET
|
PIONEERING MARKETDIGITS CONSULTING AND ADVISORY PRIVATE LIMITED
Richmond, Feb. 06, 2024 (GLOBE NEWSWIRE) -- According to a research report "Advanced Therapy Medicinal Products Market”, by Therapy Type (Cell Therapy {Stem Cell Therapy, Non-stem Cell Therapy},...
BioNTech präsentiert positives Daten-Update aus der Phase-1/2-Studie mit dem CAR-T-Zelltherapiekandidat BNT211 bei fortgeschrittenen soliden Tumoren auf dem ESMO-Kongress 2023
October 23, 2023 11:30 ET
|
BioNTech SE
BNT211 hat das Potential, die erste Therapie dieser Art zu werden, indem der Kandidat zwei innovative Ansätze kombiniert: eine autologe CAR-T-Zelltherapie mit dem onkofetalen Antigen Claudin-6 (CLDN6)...
BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023
October 23, 2023 11:30 ET
|
BioNTech SE
BNT211 combines two innovative approaches in one regimen with first-in-class potential: an autologous CAR-T cell therapy targeting the oncofetal antigen Claudin-6 (CLDN6) and a CLDN6-encoding CAR-T...
The CAR-T cell therapy market is projected to grow at an annualized rate of 23%, claims Roots Analysis
February 15, 2023 10:00 ET
|
Roots Analysis
London, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Global CAR-T Cell Therapy Market (4th Edition), 2022-2035 ” report to its list of offerings. CAR-T cell...
CAR-T Therapy market is projected to grow at a CAGR of 42.95% by 2032: Visiongain Reports Ltd
December 29, 2022 09:00 ET
|
Visiongain Reports Ltd
Visiongain has published a new report entitled CAR-T Therapy Market 2022-2032. It includes profiles of CAR-T Therapy and Forecasts Market Segment by Indication {Diffuse Large B-Cell Lymphoma (DLBCL), ...
CAR-T Therapy market is projected to grow at a CAGR of 42.95% by 2032: Visiongain Reports Ltd
November 02, 2022 11:10 ET
|
Visiongain Reports Ltd
Visiongain has published a new report entitled CAR-T Therapy Market 2022-2032. It includes profiles of CAR-T Therapy and Forecasts Market Segment by Indication {Diffuse Large B-Cell Lymphoma (DLBCL), ...